/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Akero Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$54.33 0.0037(0.37%) AKRO at 04 Dec 2025 04:25 PM Biotechnology
Lowest Today 54.455
Highest Today 54.7
Today’s Open 54.51
Prev. Close 54.49
52 Week High 58.40
52 Week Low 21.34
Day’s Range: Low 54.455 High 54.7
52-Week Range: Low 21.34 High 58.40
1 day return -
1 Week return +0.59
1 month return +1.23
3 month return +24.25
6 month return +3.1
1 year return +76.85
3 year return +24.19
5 year return +91.6
10 year return -

Institutional Holdings

HHG PLC 8.42

BlackRock Inc 7.23

General Atlantic Llc 7.17

RTW INVESTMENTS, LLC 6.85

Vanguard Group Inc 5.66

T. Rowe Price Associates, Inc. 5.64

venBio Select Advisor LLC 4.38

Wellington Management Company LLP 4.26

Deep Track Capital, LP 3.80

State Street Corp 3.43

Point72 Asset Management, L.P. 3.39

Woodline Partners LP 3.08

Vanguard Total Stock Mkt Idx Inv 3.01

UBS Group AG 2.54

Bellevue Group AG 2.48

Alkeon Capital Management, LLC 2.31

Geode Capital Management, LLC 2.15

iShares Russell 2000 ETF 2.11

US Small-Cap Growth II Equity Comp 2.03

AllianceBernstein L.P. 1.92

Janus Henderson Global Life Sciences 1.80

Janus Henderson Global Life Sciences D 1.80

Marshall Wace Asset Management Ltd 1.77

T. Rowe Price New Horizons 1.68

Bank of America Corp 1.65

Vanguard Health Care Inv 1.57

Logos Global Management LP 1.50

Janus Global Life Science AUSD 1.48

SPDR® S&P Biotech ETF 1.42

T. Rowe Price Health Sciences 1.38

Janus Henderson Glb Life Scn I2 USD 1.36

ACAP Strategic A 1.11

Vanguard Institutional Extnd Mkt Idx Tr 0.98

Fidelity Small Cap Index 0.88

iShares Russell 2000 Growth ETF 0.77

T. Rowe Price New Horizons Tr-A 0.68

Polar Capital Biotech S Inc 0.63

Pictet-Biotech P USD 0.60

iShares Biotechnology ETF 0.53

AB Small Cap Growth A 0.53

Market Status

Strong Buy: 9

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 4485.41 M

PB Ratio 4.6727

PE Ratio 0.0

Enterprise Value 3738.05 M

Total Assets 825.89 M

Volume 3677687

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:115156000 115.2M, FY21:-100886000 -100.9M, FY20:-80154000 -80.2M, FY19:null 0.0M

Annual Net worth FY23:-119632000 -119.6M, FY22:-108910000 -108.9M, FY21:-100736000 -100.7M, FY20:-79190000 -79.2M, FY19:-43755000 -43.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:-1000 -0.0M

Quarterly Net worth Q3/2025:-81566000 -81.6M, Q2/2025:-70505000 -70.5M, Q1/2025:-70725000 -70.7M, Q3/2024:-72705000 -72.7M, Q2/2024:-55987000 -56.0M

Fund house & investment objective

Company Information Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 74

Industry Biotechnology

CEO Dr. Andrew Cheng M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow